Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc. is a biotechnology company specializing in the development and commercialization of medicines for immune-mediated ocular and systemic diseases. The company's primary focus is on its lead product candidate, reproxalap, a reactive aldehyde species (RASP) modulator, currently in Phase III clinical trials for the treatment of dry eye diseases and allergic conjunctivitis. Additionally, the company is developing ADX-629, a first-in-class orally administered RASP modulator in Phase II clinical trials for psoriasis, asthma, and COVID-19, as well as ADX-2191, a dihydrofolate reductase inhibitor in Phase III for the prevention of proliferative vitreoretinopathy and Phase II for the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma.

Products

• Reproxalap for dry eye diseases and allergic conjunctivitis

• ADX-629 for psoriasis, asthma, and COVID-19

• ADX-2191 for proliferative vitreoretinopathy, retinitis pigmentosa, and primary vitreoretinal lymphoma